title: The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse.
abstract: Cannabinoid CB1 antagonists decrease self-administration of palatable food and several abused drugs in animals and modulate extinction of conditioned fear responses. Less is known, however, about whether and how CB1 antagonists might modulate the extinction of appetitive behavior. Therefore, this study examined the effects of the CB1 receptor antagonist rimonabant (SR141716) during extinction of responding maintained either by cocaine or by palatable foods (corn oil or Ensure), as well as responding elicited by stimulus cues that had been paired with the presentation of cocaine (i.e., cue-induced reinstatement) or a prime (presentation of cocaine or food). The effect of rimonabant on high rate responding in water-deprived mice trained to self-administer water was also examined. In mice self-administering cocaine, rimonabant attenuated cue-induced reinstatement of cocaine self-administration, the initial burst of responding during cocaine extinction and responding during spontaneous recovery. In mice self-administering corn oil, rimonabant decreased responding during extinction and also attenuated responding that had been reinstated by a priming presentation of corn oil. Moreover, mice treated with rimonabant required fewer daily sessions to reach criterion for extinction of cocaine-maintained responding than vehicle treated mice. Also, rimonabant had no effect on the rate of operant responding in mice trained to respond for water under an FR5 schedule of reinforcement. Taken together, these data suggest that in addition to attenuating the primary reinforcing effects of both palatable foods and drugs of abuse, CB1 receptor antagonism can attenuate context and cue reactivity during extinction learning and potentially enhance extinction learning in this way.
authors.affiliation: Temple University School of Pharmacy, 3307 North Broad Street, Philadelphia, PA 19140, United States. saraward@temple.edu
authors.forename: Sara Jane
authors.initials: SJ
authors.lastname: Ward
authors.forename: Marisa
authors.initials: M
authors.lastname: Rosenberg
authors.forename: Linda A
authors.initials: LA
authors.lastname: Dykstra
authors.forename: Ellen A
authors.initials: EA
authors.lastname: Walker
mesh_terms: D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy; D003042:Cocaine / Q000008:administration & dosage*; D019970:Cocaine-Related Disorders / Q000188:drug therapy / Q000517:prevention & control*; D003216:Conditioning, Operant / Q000187:drug effects; D003314:Corn Oil / Q000008:administration & dosage; D003463:Cues; D019422:Dietary Sucrose / Q000008:administration & dosage; D004195:Disease Models, Animal; D005108:Extinction, Psychological / Q000187:drug effects*; D005526:Food, Formulated; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D012008:Recurrence; D012055:Reinforcement Schedule; D000077285:Rimonabant; D012646:Self Administration / Q000523:psychology*; D014867:Water / Q000008:administration & dosage
chemical_list: D019422:Dietary Sucrose; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D014867:Water; C082131:Ensure formulated food; D003314:Corn Oil; D003042:Cocaine; D000077285:Rimonabant
references.citation: NIDA Res Monogr. 1993;137:73-95
references.pmid: 8289929
references.citation: J Appl Behav Anal. 1995 Spring;28(1):93-4
references.pmid: 16795857
references.citation: Psychopharmacology (Berl). 2007 Apr;191(2):223-31
references.pmid: 17211653
references.citation: Eur J Pharmacol. 2003 Sep 23;477(3):213-7
references.pmid: 14522359
references.citation: Psychopharmacology (Berl). 2005 May;179(2):452-60
references.pmid: 15821957
references.citation: Behav Res Ther. 1992 May;30(3):235-41
references.pmid: 1586360
references.citation: Psychopharmacology (Berl). 2006 Nov;188(4):641-9
references.pmid: 16947018
references.citation: Psychopharmacology (Berl). 2003 Feb;165(4):370-7
references.pmid: 12447606
references.citation: J Comp Physiol Psychol. 1956 Aug;49(4):381-91
references.pmid: 13345917
references.citation: Behav Pharmacol. 2005 Sep;16(5-6):381-8
references.pmid: 16148442
references.citation: Trends Pharmacol Sci. 2005 Aug;26(8):420-6
references.pmid: 15992935
references.citation: Neuropsychopharmacology. 2008 Jun;33(7):1735-45
references.pmid: 17728698
references.citation: Exp Neurol. 1963 Jan;7:65-75
references.pmid: 14017412
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):21-30
references.pmid: 12695875
references.citation: Eur J Pharmacol. 2000 Sep 15;404(1-2):175-9
references.pmid: 10980277
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):164-169
references.pmid: 12669182
references.citation: Learn Mem. 2008 Oct 28;15(11):806-9
references.pmid: 18957525
references.citation: Psychopharmacology (Berl). 2008 Sep;199(4):593-603
references.pmid: 18488200
references.citation: Pharmacol Rep. 2006 Nov-Dec;58(6):806-19
references.pmid: 17220538
references.citation: Behav Pharmacol. 2002 Sep;13(5-6):451-63
references.pmid: 12394421
references.citation: Nat Med. 2001 Oct;7(10):1151-4
references.pmid: 11590440
references.citation: Learn Mem. 2004 Sep-Oct;11(5):611-6
references.pmid: 15466316
references.citation: J Pharmacol Exp Ther. 2003 Jul;306(1):93-102
references.pmid: 12660305
references.citation: Psychopharmacology (Berl). 1997 Jul;132(1):104-6
references.pmid: 9272766
references.citation: Neuropsychopharmacology. 2009 Aug;34(9):2072-80
references.pmid: 19322169
references.citation: Psychopharmacology (Berl). 1999 Nov;147(1):22-4
references.pmid: 10591861
references.citation: Eur J Pharmacol. 2005 Mar 7;510(1-2):69-74
references.pmid: 15740726
references.citation: Pharmacol Rev. 2007 Jun;59(2):151-84
references.pmid: 17540905
references.citation: Addict Behav. 1990;15(4):355-65
references.pmid: 2248109
references.citation: Eur J Neurosci. 2005 Apr;21(8):2243-51
references.pmid: 15869521
references.citation: J Pharmacol Exp Ther. 2008 May;325(2):567-76
references.pmid: 18256173
references.citation: Psychopharmacology (Berl). 2005 Jun;179(4):863-72
references.pmid: 15619104
references.citation: Mol Neurobiol. 2007 Aug;36(1):92-101
references.pmid: 17952654
references.citation: Neuropsychopharmacology. 2007 Dec;32(12):2592-600
references.pmid: 17392737
references.citation: Mol Psychiatry. 2007 Feb;12(2):120-50
references.pmid: 17160066
references.citation: Biol Psychiatry. 2002 Nov 15;52(10):976-86
references.pmid: 12437938
references.citation: Physiol Behav. 2008 Mar 18;93(4-5):666-70
references.pmid: 18076956
references.citation: J Clin Psychiatry. 1988 Feb;49 Suppl:17-22
references.pmid: 3276670
references.citation: Neuroscience. 2007 Jun 8;146(4):1484-94
references.pmid: 17449185
references.citation: Brain Res. 2003 May 23;973(1):99-106
references.pmid: 12729958
references.citation: Nature. 2002 Aug 1;418(6897):530-4
references.pmid: 12152079
references.citation: Neuropsychopharmacology. 2004 Aug;29(8):1470-8
references.pmid: 15085091
references.citation: Neuropsychopharmacology. 2005 Sep;30(9):1670-80
references.pmid: 15742004